
Sarwa Darwish Murad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8523719/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pregnancy outcomes in women with Budd–Chiari syndrome or portal vein thrombosis – a multicent retrospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 608-617.	re 1.1	7
2	Baveno VII – Renewing consensus in portal hypertension. Journal of Hepatology, 2022, 76, 959-974.	1.8	890
3	Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Populationâ€Based Study of 1,355 Adults. Hepatology, 2021, 73, 968-982.	3.6	43
4	Donor diabetes mellitus is a risk factor for diminished outcome after liver transplantation: a nationwide retrospective cohort study. Transplant International, 2021, 34, 110-117.	0.8	4
5	Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 1483-1492.	0.7	13
6	Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial. New England Journal of Medicine, 2021, 384, 1391-1401.	13.9	305
7	Medication-Related Problems in Liver Transplant Recipients in the Outpatient Setting: A Dutch Cohort Study. Frontiers in Pharmacology, 2021, 12, 637090.	1.6	4
8	Recurrence of primary sclerosing cholangitis after liver transplantation – analysing the European Liver Transplant Registry and beyond. Transplant International, 2021, 34, 1455-1467.	0.8	23
9	Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Alimentary Pharmacology and Therapeutics, 2021, 53, 432-442.	1.9	9
10	Animal protein intake and hepatic steatosis in the elderly: authors' response. Gut, 2020, 69, 189.1-189.	6.1	1
11	Impact of preoperative liver dysfunction on outcomes in patients with left ventricular assist devices. European Journal of Cardio-thoracic Surgery, 2020, 57, 920-928.	0.6	9
12	Disadvantage of Small (<60 kg) Adult Candidates on the Liver Transplantation Waitlist. Progress in Transplantation, 2020, 30, 349-354.	0.4	5
13	Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis. TH Open, 2020, 04, e224-e230.	0.7	6
14	Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant – a pilot study. Transplant International, 2020, 33, 1424-1436.	0.8	8
15	Donor hepatectomy time influences ischemia-reperfusion injury of the biliary tree in donation after circulatory death liverÂtransplantation. Surgery, 2020, 168, 160-166.	1.0	15
16	Selected liver grafts from donation after circulatory death can be safely used for retransplantation – a multicenter retrospective study. Transplant International, 2020, 33, 667-674.	0.8	4
17	Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug–metabolite atlas. Nature Medicine, 2020, 26, 110-117.	15.2	54
18	The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Clinical and Translational Gastroenterology, 2020, 11, e00170.	1.3	12

#	Article	IF	CITATIONS
19	Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. European Journal of Epidemiology, 2020, 35, 1069-1085.	2.5	35
20	Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut, 2019, 68, 1088-1098.	6.1	97
21	Diet-Dependent Acid Load—The Missing Link Between an Animal Protein–Rich Diet and Nonalcoholic Fatty Liver Disease?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6325-6337.	1.8	14
22	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. Journal of Hepatology, 2019, 71, 1141-1151.	1.8	104
23	Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. Journal of Bone and Mineral Research, 2019, 34, 1254-1263.	3.1	53
24	Combined liverâ€kidney transplantation: two for the price of one?. Transplant International, 2019, 32, 913-915.	0.8	0
25	Porto-sinusoidal vascular disease: proposal and description of a novel entity. The Lancet Gastroenterology and Hepatology, 2019, 4, 399-411.	3.7	149
26	A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease. Diabetes, 2019, 68, 1073-1083.	0.3	41
27	NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter. Journal of Hepatology, 2019, 70, 1302-1303.	1.8	3
28	High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. Transplantation, 2019, 103, 2329-2337.	0.5	15
29	Range of Normal Liver Stiffness and Factors Associated WithÂlncreased Stiffness Measurements in Apparently HealthyÂlndividuals. Clinical Gastroenterology and Hepatology, 2019, 17, 54-64.e1.	2.4	59
30	Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infections. European Journal of Gastroenterology and Hepatology, 2019, 31, 1444-1451.	0.8	5
31	Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab. ACG Case Reports Journal, 2019, 6, e00243.	0.2	21
32	Genomic sequence of yellow fever virus from a Dutch traveller returning from the Gambia-Senegal region, the Netherlands, November 2018. Eurosurveillance, 2019, 24, .	3.9	9
33	Sarcopenia and Its Clinical Correlates in the General Population: The Rotterdam Study. Journal of Bone and Mineral Research, 2018, 33, 1209-1218.	3.1	51
34	Reply to: "Association between beverage consumption and liver fibrosis― Journal of Hepatology, 2018, 68, 1096-1098.	1.8	0
35	A nomogram with sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant patients: a competing risk analysis in a national cohort. Journal of Hepatology, 2018, 68, S377-S378.	1.8	2
36	Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study. Journal of Hepatology, 2018, 68, S555.	1.8	0

#	Article	IF	CITATIONS
37	A rare missense variant in RCL1 segregates with depression in extended families. Molecular Psychiatry, 2018, 23, 1120-1126.	4.1	34
38	Reply to: "Herbal tea consumption and the liver – All is not what is seems!― Journal of Hepatology, 2018, 68, 613-614.	1.8	1
39	Low skeletal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation-a retrospective study. Transplant International, 2018, 31, 165-174.	0.8	64
40	FP043RENAL CYSTS IN THE GENERAL POPULATION: ASSOCIATIONS WITH KIDNEY FUNCTION AND MORTALITY. Nephrology Dialysis Transplantation, 2018, 33, i62-i62.	0.4	0
41	Differences in the Colon Microbiome between Patients with and without Recurrence of Primary Sclerosing Cholangitis. Transplantation, 2018, 102, S721.	0.5	0
42	Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial. Journal of Hepatology, 2018, 68, S123-S124.	1.8	4
43	<i>Helicobacter pylori</i> and the risk of dementia: A populationâ€based study. Alzheimer's and Dementia, 2018, 14, 1377-1382.	0.4	33
44	Potential Mechanisms Underlying the Role of Coffee in Liver Health. Seminars in Liver Disease, 2018, 38, 193-214.	1.8	23
45	Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication in a population-based cohort. Molecular Psychiatry, 2018, 23, 1093-1093.	4.1	0
46	Transient elastography for screening of liver fibrosis in the population: A cost-effectiveness analysis using prospective databases from 6 countries in Europe and Asia. Journal of Hepatology, 2018, 68, S157.	1.8	0
47	A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. Journal of Hepatology, 2018, 68, 707-714.	1.8	161
48	Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study. Journal of Hepatology, 2017, 66, S420-S421.	1.8	0
49	Normal Values of Liver Stiffness as Measured by Transient Elastography: Pooled Individual Participant Data Meta-Analysis from 26 Studies and 14,883 Participants. Gastroenterology, 2017, 152, S1106.	0.6	0
50	Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 187-198.	1.0	42
51	Epigenome-Wide Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic Steatosis. Gastroenterology, 2017, 153, 1096-1106.e2.	0.6	52
52	Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. Journal of Hepatology, 2017, 67, 339-348.	1.8	56
53	Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian randomization study. International Journal of Epidemiology, 2017, 46, 1400-1409.	0.9	21
54	Screening studies of transient elastography and FibroTest in the general population – Authors' reply. The Lancet Gastroenterology and Hepatology, 2017, 2, 246-247.	3.7	0

#	Article	IF	CITATIONS
55	Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). British Journal of Dermatology, 2017, 176, 1599-1606.	1.4	18
56	The Rotterdam Study: 2018 update on objectives, design and main results. European Journal of Epidemiology, 2017, 32, 807-850.	2.5	379
57	Animal protein is the most important macronutrient associated with non-alcoholic fatty liver disease in overweight participants: The Rotterdam Study. Journal of Hepatology, 2017, 66, S50.	1.8	3
58	Recurrence of primary sclerosing cholangitis is associated with lower survival after liver transplantation: an analysis of the European liver transplant registry data base. Journal of Hepatology, 2017, 66, S200.	1.8	1
59	Normal values of liver stiffness as measured by transient elastography: pooled individual participant data meta-analysis from 26 studies and 14,883 participants. Journal of Hepatology, 2017, 66, S238.	1.8	0
60	ls liver stiffness equal to liver fibrosis?. Hepatology, 2017, 65, 749-749.	3.6	4
61	Reply. Hepatology, 2017, 65, 749-750.	3.6	1
62	The invasion of fatty liver disease in liver transplantation. Transplant International, 2016, 29, 416-417.	0.8	4
63	Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology and Hepatology, 2016, 1, 256-260.	3.7	131
64	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology, 2016, 63, 138-147.	3.6	253
65	Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. Gastroenterology, 2016, 151, 351-363.e28.	0.6	74
66	Cholestasis is not Associated with Liver Stiffness in a Population-Based Cohort. Journal of Hepatology, 2016, 64, S721.	1.8	0
67	Liver fat is related to cardiovascular risk factors and subclinical vascular disease: the Rotterdam Study. European Heart Journal Cardiovascular Imaging, 2016, 17, 1361-1367.	0.5	33
68	Longterm clinical and radiological followâ€up of living liver donors. Liver Transplantation, 2016, 22, 934-942.	1.3	22
69	Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3204-3211.	1.8	138
70	P0983 : Association between macro-nutrient intake and presence of nonalcoholic fatty liver disease in the Rotterdam study: a population-based study. Journal of Hepatology, 2015, 62, S715.	1.8	0
71	Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol. Transplant International, 2015, 28, 1383-1391.	0.8	7
72	P1286 : Low prevalence of positive viral serology for HBV and HCV among a general dutch elderly population: Results from the rotterdam study. Journal of Hepatology, 2015, 62, S841.	1.8	1

#	Article	IF	CITATIONS
73	Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population. Journal of Hepatology, 2015, 63, 1459-1465.	1.8	31
74	Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. Haematologica, 2015, 100, e226-e228.	1.7	39
75	The Rotterdam Study: 2016 objectives and design update. European Journal of Epidemiology, 2015, 30, 661-708.	2.5	358
76	Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study. Gut, 2015, 64, 692-694.	6.1	3
77	O79 PROTHROMBOTIC GENETIC RISK FACTORS ARE ASSOCIATED WITH LIVER STIFFNESS IN THE GENERAL POPULATION: RESULTS FROM THE ROTTERDAM STUDY. Journal of Hepatology, 2014, 60, S32-S33.	1.8	0
78	The Rotterdam Study: 2014 objectives and design update. European Journal of Epidemiology, 2013, 28, 889-926.	2.5	282
79	Liver Transplantation for Perihilar Cholangiocarcinoma. Digestive Diseases, 2013, 31, 126-129.	0.8	70
80	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology, 2013, 57, 1962-1968.	3.6	237
81	Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. Liver Transplantation, 2013, 19, 521-528.	1.3	25
82	Fibrinogen γ' and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis. Thrombosis and Haemostasis, 2013, 109, 558-560.	1.8	6
83	Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. Journal of Thrombosis and Haemostasis, 2012, 10, 2116-2122.	1.9	76
84	Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers. Gastroenterology, 2012, 143, 88-98.e3.	0.6	475
85	Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology, 2012, 56, 972-981.	3.6	119
86	Neoadjuvant Therapy and Liver Transplantation for Hilar Cholangiocarcinoma: Is Pretreatment Pathological Confirmation of Diagnosis Necessary?. Journal of the American College of Surgeons, 2012, 215, 31-38.	0.2	72
87	The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood, 2011, 117, 3968-3973.	0.6	43
88	Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd–Chiari syndrome. Journal of Hepatology, 2011, 54, 908-914.	1.8	12
89	Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood, 2010, 115, 388-395.	0.6	43
90	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010, 51, 210-218.	3.6	458

Sarwa Darwish Murad

#	Article	IF	CITATIONS
91	JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis. Blood, 2010, 116, 4212-4212.	0.6	4
92	Fibrinogen γ' In the Budd-Chiari Syndrome: Results From a Multicenter Case-Control Study. Blood, 2010, 116, 4213-4213.	0.6	0
93	Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study. Journal of Hepatology, 2009, 51, 696-706.	1.8	98
94	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. Annals of Internal Medicine, 2009, 151, 167.	2.0	422
95	Liver transplantation for Budd-Chiari syndrome: When is it really necessary?. Liver Transplantation, 2008, 14, 133-135.	1.3	9
96	Longâ€ŧerm outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd–Chiari syndrome. Liver International, 2008, 28, 249-256.	1.9	44
97	Early changes of the portal tract on microcomputed tomography images in a newlyâ€developed rat model for Budd–Chiari syndrome. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1561-1566.	1.4	9
98	TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostics Factors in 124 Patients. Gastroenterology, 2008, 135, 808-815.	0.6	319
99	Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointestinal Endoscopy, 2008, 67, 821-827.	0.5	46
100	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood, 2008, 111, 4922-4929.	0.6	319
101	[3] A PROSPECTIVE FOLLOW-UP STUDY ON 163 PATIENTS WITH BUDD-CHIARI SYNDROME: RESULTS FROM THE EUROPEAN NETWORK FOR VASCULAR DISORDERS OF THE LIVER (EN-VIE). Journal of Hepatology, 2007, 46, S4.	1.8	18
102	[83] TREATMENT OF BUDD CHIARI SYNDROME WITH TIPS. LONG-TERM RESULTS IN 124 PATIENTS AND EVALUATION OF PROGNOSTIC FACTORS. Journal of Hepatology, 2007, 46, S36-S37.	1.8	1
103	Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?. Liver Transplantation, 2007, 13, 867-874.	1.3	29
104	Solubility analysis of buspirone hydrochloride polymorphs: Measurements and prediction. International Journal of Pharmaceutics, 2007, 338, 55-63.	2.6	35
105	Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thrombosis and Haemostasis, 2007, 97, 181-185.	1.8	26
106	Endoscopic Ultrasound (EUS) Guided Drainage of Pseudocysts: Safer and More Effective Compared to Standard Endoscopic Drainage. Gastrointestinal Endoscopy, 2006, 63, AB266.	0.5	3
107	Pathogenesis and Treatment of Budd-Chiari Syndrome Combined with Portal Vein Thrombosis. American Journal of Gastroenterology, 2006, 101, 83-90.	0.2	102
108	Response to Dr. Senzolo et al American Journal of Gastroenterology, 2006, 101, 2164-2165.	0.2	1

#	Article	IF	CITATIONS
109	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD Blood, 2006, 108, 377-377.	0.6	8
110	Evidence for an Enhanced Fibrinolytic Capacity in Liver Cirrhosis Measured with a New Global Fibrinolysis Test in Whole Blood Blood, 2006, 108, 1627-1627.	0.6	26
111	Myeloproliferative Disease in the Pathogenesis and Survival of Budd-Chiari Syndrome Blood, 2006, 108, 1480-1480.	0.6	1
112	Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica, 2006, 91, 1712-3.	1.7	58
113	Determinants of self-reported emotional and behavioral problems in Turkish immigrant adolescents aged 11?18. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 196-207.	1.6	30
114	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology, 2004, 39, 500-508.	3.6	315
115	Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology, 2004, 39, 804-810.	3.6	321
116	Predictors of self-reported problem behaviours in Turkish immigrant and Dutch adolescents in the Netherlands. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2003, 44, 412-423.	3.1	69
117	Aetiology, treatment and prognosis of patients with combined Budd-Chiari syndrome and portal vein thrombosis. Journal of Hepatology, 2003, 38, 216.	1.8	0